Purpose {#Sec1}
=======

The COVID-19 pandemic has affected more than 3 million people worldwide and 25,000 have died in Spain as of 2nd May 2020 \[[@CR1]\] and healthcare stakeholders have taken challenging decisions to safeguard public health. In Spain, on March 14th, the government declared the state of alarm \[[@CR2]\]. As a consequence, the Spanish healthcare system has suffered unprecedented adjustments to prioritize resources for the fight against COVID-19 \[[@CR3]\]. Outpatient follow-up and elective procedures have been cancelled and healthcare providers reallocated to assist patients with COVID-19.

Although SARS-CoV-2 is suspected to infect children milder than adults \[[@CR4]\], adjustment of healthcare facilities has been established also for them \[[@CR5], [@CR6]\].

The countermeasures adopted by the authorities can impact hardly in clinical research, which often is perceived as a "desirable but not essential" activity. Actions undertaken can affect the conduct of clinical trials in many ways \[e.g., completion of trial assessments, visits, and provision of investigational medicinal products (IMPs)\]. Furthermore, pharmaceutical companies may refocus resources into areas related to COVID-19 (e.g., vaccines or antiviral drugs), thus affecting other research areas.

This situation forces sponsors, investigators, and patients to adapt. The European Medicines Agency and the Spanish Agency of Medicines and Medical Devices have issued guidelines on the management of clinical trial activities \[[@CR7], [@CR8]\] Both are aligned in the intention to guarantee trial activity, patient safety, and action traceability. However, all parties (i.e., healthcare authorities, hospitals, regulators, and sponsors) have implemented measures differently depending on the impact of the pandemic in their regions and their capacity to adapt, although not all coordinated nor evidence-based.

Cancer research is particularly challenging, because patients are remarkably vulnerable: their baseline condition needs close surveillance and delays in diagnosis or treatment are potentially fatal \[[@CR9]\]; in parallel, cancer patients are at increased risk for severe COVID-19 disease \[[@CR10]--[@CR12]\]

We evaluated the impact of the COVID-19 pandemic on the early phase clinical trial activity in paediatric oncology during the first month of state of alarm in Spain (14th March--12th April 2020).

Methods {#Sec2}
=======

In Spain, the Innovative Therapies for Children with Cancer consortium (ITCC), an international scientific organisation dedicated to early drug development for childhood cancers in 56 centres from 14 European countries, has accredited five paediatric cancer centres to deliver early phase clinical trials \[[@CR13]\]. All five centres were contacted and sent a 93-item questionnaire between 13th and 19th April 2020 investigating the impact of the pandemic on actively recruiting phase I--II clinical trials in solid and haematological paediatric malignancies and on molecular cancer platforms (Appendix I).

Descriptive statistics of the survey are provided.

Results {#Sec3}
=======

Impact on staff {#Sec4}
---------------

All units suffered shortages on on-site staff in all professional strata (Table [1](#Tab1){ref-type="table"}). The median decrease in personnel was 59% (range 33--100). Main causes were: institutional contingency policies (88%), COVID-19-infected workers (7%), and relocation to other hospital areas (5%).Table 1Summary of responses to the survey provided by the five early phase clinical trials unitsItemsTotal, *n*Total, %\*\**Baseline data\**Phase I trials active, recruiting27Phase II trials active, recruiting57Molecular platforms active, recruiting2Total phase I--II trials or molecular platforms active, recruiting86 H Vall d'Hebron25 H Sant Joan de Deu8 H La Fe18 H La Paz9 H Niño Jesús26Phase I trials active, not yet recruiting8Phase II trials active, not yet recruiting8SIV previously scheduled for March/April 202010MV previously scheduled for March/April 202049Unit's full-time workers73Total of patients recruited in Phase I/II studies during 201998*Impact on personnel*Number of units suffering shortages of on-site staff5100% (5/5)Total reduction in number of on-site workers4359% (43/73)*Cause of personnel reduction*:COVID-19-infected workers37% (3/43)Institutional contingency policy (i.e., home-based work)3888% (38/43)Relocation to other areas to work on COVID-1925% (2/43)Units performing remote data entry5100% (5/5)Units with appropriate tools for homeworking360% (3/5)Impact on on-site activities performed by the sponsorsUnits suffering SIV delays/cancellation480% (4/5)Number of SIV postponed770% (7/10)Postponing SIV decided by: Sponsor7100% (7/7) Investigators00% Institution00%Number of SIV performed remotely330% (3/10)Units suffering MV delays/cancellation5100% (5/5)Number of MV postponed3673% (36/49)*Postponing MV decided by:*Institution2570% (25/36)Investigators00%Sponsor + Institution1130% (11/36)Number of MV performed remotely1327%*Impact on recruitment*Units continuing recruitment480% (4/5)Units with restrictions to accept new referrals480% (4/5)New patients recruited to early phase trials\*\*\*2*Trials with recruitment stopped*H Vall d'Hebron624% (6/25)H Sant Joan de Deu675% (6/8)H La Fe18100% (18/18)H La Paz222% (2/9)H Niño Jesús623% (6/26)*Recruitment stop decided by:*Sponsor1847% (18/38)Investigators00%Institution2053% (20/38)Impact on IMP and research devicesTrials with IMP shortages00%Units shipping IMPs to the patient's home or to the local healthcare institution240% (2/5)Trials in which IMP were shipped to the patient's home or to the local healthcare centres67% (6/84)Units in which the sponsor facilitated the shipment of IMP to patients5100% (5/5)Units managing to increase IMP supplies to patients360% (3/5)Trials managing to increase IMP supplies to patients1518% (15/84)Trials suffering shortages of research devices (e.g., sample kits)00%Units with difficulties to send out research samples00%*Impact on patient care organization*Units suffering restrictions to treat patients5100% (5/5)Total number of patient visits conducted143 Patient visits conducted on-site11077% (110/143) Patient visits conducted in other healthcare facilities139% (13/143) Patient visits conducted by phone2014% (20/143)Patient visits rescheduled1410% (14/143)Patient visits cancelled00%Units which received sponsor's agreement to conduct patient visits in other health care institutions5100% (5/5)Patients suffering treatment delays1*Cause for patients suffering treatment delay:*Not possible to ensure IMP supply00%Not possible to ensure safety00%Patient/parents' decision1100% (1/1)Patients suffering treatment discontinuation0Units suffering restriction to perform trial assessments240% (2/5)Patients not being able to be recruited into potential trials7*Alternative provided to patients not being able to be recruited into trials*No treatment343% (3/7)Out-of-trial treatment457% (4/7)Inclusion in a trial elsewhere0*Decision not to include patients taken by:*Sponsor343% (3/7)Investigators457% (4/7)Institution00%Patient/parents00%Impact on legal aspectsPending contracts postponed3Units approached with sponsor contingency plans for the management of issues related to the COVID-19 crisis5100% (5/5)Units creating individual contingency plans for the management of issues related to the COVID-19 crisis5100% (5/5)*Future perspectives*Unit Leads expecting lower recruitment rates in 2020 compared to 20195100% (5/5)Unit Leads planning changes in organization for the next months to promote home working and remote MVs or SIVs480% (4/5)Unit Leads thinking this crisis will make them better prepared for future crises5100% (5/5)

All units managed to perform remote data entry, although two were not fully equipped for and had difficulties to perform their activities.

Impact on on-site activities performed by the sponsors {#Sec5}
------------------------------------------------------

Seventy percent (7/10) planned site initiation visits (SIV) were postponed and 30% (*n* = 3) were performed remotely, all as per decision of the sponsor.

Seventy-three percent (36/49) planned monitoring visits (MV) which were postponed and 27% (*n* = 13) were performed remotely, mostly due to institutional decision (70%).

Impact on recruitment {#Sec6}
---------------------

The median number of studies that stopped recruitment per site was 6 (range 2--6), a 49% on average (SD 32.5) of actively recruiting studies. The decision to stop was taken per sponsor (47%) or per local institutions (53%). One unit interrupted recruitment in all trials (*n* = 18) following institutional decision. During this period, only two new patients were enrolled across the whole of Spain, 75% less than the monthly average in 2019 (*n* = 8).

Impact on organization of patient care {#Sec7}
--------------------------------------

All units continued on-site patient care with limitations. Two units had restrictions to perform assessments due to local prevention strategies.

Out of 143 planned patient visits, 15 (10%) had to be rescheduled. Most were conducted on-site (77%, 110), while 14% (20) were conducted by phone and 9% (13) in other hospitals closer to family home. Only one patient experienced treatment delay (parents' decision).

Seven patients that were potentially eligible could not be enrolled. Of those, four received non-trial treatments and three are on standby. The reasons for not enrolling were: recruitment interrupted by sponsor (*n* = 3) and not considered safe to be included by investigators (*n* = 4)

Impact on supply of investigational medicinal product and research devices {#Sec8}
--------------------------------------------------------------------------

Provision of IMPs and research devices, as well as shipment of research samples, were uniformly warranted. For six trials, two units were able to ship IMPs to patients' homes or to local hospitals. Three units provided larger amounts of trial medications to patients to minimise hospital visits.

Impact on legal and regulatory aspects {#Sec9}
--------------------------------------

The completion of three planned contracts was delayed. All units have been provided with contingency plans by sponsors and have also created individual plans for the management of COVID-19-related issues.

Future perspective {#Sec10}
------------------

All investigators foresee a lower recruitment in 2020 compared to 2019. Most are planning changes over the next months to promote homeworking and remote SIVs/MVs. All investigators believe that this crisis will make units better prepared for future crises.

Following the analysis of this survey results and the collected expert consensus, we propose a set of recommendations to preserve patient safety, scientific integrity, and research value (Fig. [1](#Fig1){ref-type="fig"}).

![Set of recommendations to preserve patient safety, scientific integrity and research value](12094_2020_2399_Fig1_HTML){#Fig1}

Conclusions {#Sec11}
===========

This study reveals that paediatric cancer clinical research has been significantly impacted by the COVID-19 pandemic.

Shortage of personnel has been a major issue in all units, as a consequence of contingency plans restricting on-site work. While physicians and nurses' activities have been severely compromised as their activities are essentially patient-centred, it may have less impact on other professional strata such as study coordinators or data managers, provided that they have appropriate means to perform their work remotely. Unfortunately, this was not the case for all institutions. Providing homeworking solutions is essential under the perspective of sustained restrictions over the next months. Although redeployment of staff to other areas in the fight against COVID-19 is necessary, it has an undeniable impact on areas with highly specialized, multidisciplinary activities, as is clinical research.

Our study shows drastic suspension/delays of SIVs and MVs. Delays in SIV are understandable decisions because of the inherent complexity of early phase studies, but they need to be rescheduled as soon as possible. However, MVs are key to ensure safety and data quality of on-going trials, and hence, it is necessary that sponsors implement alternative mechanisms to resume it in collaboration with the sites while preserving patient data protection (e.g., remote access to electronic medical records with regular contacts with the study coordinators).

All units have experienced restrictions in treatment delivery or ability to conduct trial assessments. Nevertheless, all units have implemented strategies to mitigate these risks while delivering treatment to the patients, complying with trial regulations and in agreement with sponsors. The outbreak is expected to increase protocol deviations, highlighting the need for a fluid communication between sites, ethics committees, sponsors, and regulators. Regulators should take a sensible approach when reviewing these deviations, especially when the trial participant's best interest has been taken into account and no additional risk has been posed \[[@CR8]\].

In our study, only one patient had his treatment delayed due to family's fears of travelling. While patients and caregivers are advised to restrict hospital visits, they may delay medical consultation when facing adverse events during a trial. Cortiula et al. \[[@CR9]\] highlighted the negative implications of excessive focus on COVID-19 and of overshadowing the other aspects of clinical practice, especially in cancer care.

Only two patients could be recruited in this period, a 75% reduction in the expected recruitment rate, while seven potentially eligible patients could not be recruited. Clinical trials are most of the times the unique way to provide access to new drugs with significant patient benefit (e.g., TRK inhibitors for *TRK*-fusion cancers \[[@CR14]\]), or at the very least, to innovative therapies to children with no curative options. Whereas COVID-19 has a low mortality in children \[[@CR4]\], more than 90% of children with relapsed and refractory cancers will continue to die and, hence, access to novel therapies needs to be assured. Moreover, the stalling process on experimental medicines will extend the already lengthy marketing process and have an impact on the companies' market value \[[@CR15]\]. Therefore, long-term consequences of the pandemic on clinical research remain unpredictable.

Although there are multiple publications about generic emergency preparedness in health settings, there is minimal information focusing on clinical trial sites \[[@CR16], [@CR17]\] and we provide recommendations on this respect (Fig. [1](#Fig1){ref-type="fig"}).

All consulted investigators conclude that this crisis will make trial units better prepared for future emergencies and they are planning changes in their organization.

Our results show that the COVID-19 crisis has had a major impact on conducting paediatric oncology research. Our conclusions will hopefully help investigators, sponsors, and authorities to address the issues derived from this pandemic and facilitate the construction of a consensus strategy for future crises. This would allow for maintaining high-quality care, standardizing procedures, and prioritizing an efficient use of resources, to ensure safe access to therapies in the context of clinical trials.
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